Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab - PubMed
6 hours ago
- #Immunotherapy
- #Hepatocellular Carcinoma
- #Metastasis
- Extrahepatic metastases (EM) were present in 30% of HCC patients on atezolizumab/bevacizumab, most commonly in lymph nodes, lung, peritoneum, and bone.
- EM was associated with shorter progression-free survival and lower disease control rate, but not overall survival.
- Three or more EM sites significantly worsened overall survival, progression-free survival, and disease control rate.
- Patients with oligometastasis had similar outcomes to those without metastasis, while multiple metastases led to poorer survival.
- High metastatic burden negatively impacts prognosis in HCC patients treated with atezolizumab and bevacizumab.